menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Advanced Coronary Risk Assessment Insights

close
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Media formats available:
Details
Presenters
Comments
  • Overview

    Dr. Larry Kaskel welcomes Dr. James Ehrlich, chief medical officer of Atherotech and clinical associate professor in the endocrinology division of the University of Colorado School of Medicine, who has developed advanced coronary risk assessment programs in four U.S. cities. Dr. Ehrlich will describe evidence suggesting that office-based risk assessment (Framingham) fails to identify high risk individuals. He will detail which patients need advanced lipid testing as well as discuss tools and emerging biomarkers that are of highest value.

    Brought to you by:

    NLA logo

     

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Dr. Larry Kaskel welcomes Dr. James Ehrlich, chief medical officer of Atherotech and clinical associate professor in the endocrinology division of the University of Colorado School of Medicine, who has developed advanced coronary risk assessment programs in four U.S. cities. Dr. Ehrlich will describe evidence suggesting that office-based risk assessment (Framingham) fails to identify high risk individuals. He will detail which patients need advanced lipid testing as well as discuss tools and emerging biomarkers that are of highest value.

    Brought to you by:

    NLA logo

     

Facebook Comments

Schedule22 Oct 2021
Webpack App